Literature DB >> 24090997

The fusion partner specifies the oncogenic potential of NUP98 fusion proteins.

Jesslyn Saw1, David J Curtis, Damian J Hussey, Alexander Dobrovic, Peter D Aplan, Christopher I Slape.   

Abstract

NUP98 is among the most promiscuously translocated genes in hematological diseases. Among the 28 known fusion partners, there are two categories: homeobox genes and non-homeobox genes. The homeobox fusion partners are well-studied in animal models, resulting in HoxA cluster overexpression and hematological disease. The non-homeobox fusion partners are less well studied. We created transgenic animal models for three NUP98 fusion genes (one homeobox, two non-homeobox), and show that in this system, the NUP98-homeobox fusion promotes self-renewal and aberrant gene expression to a significantly greater extent. We conclude that homeobox partners create more potent NUP98 fusion oncogenes than do non-homeobox partners.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HOX; Homeobox; Leukemia; NUP98; Translocation

Mesh:

Substances:

Year:  2013        PMID: 24090997      PMCID: PMC3883578          DOI: 10.1016/j.leukres.2013.09.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  25 in total

1.  Recurrent coiled-coil motifs in NUP98 fusion partners provide a clue to leukemogenesis.

Authors:  Damian James Hussey; Alexander Dobrovic
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 2.  Focus on acute leukemias.

Authors:  D Gary Gilliland; Martin S Tallman
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

3.  A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21.

Authors:  T Mizuno; K Kaibuchi; T Yamamoto; M Kawamura; T Sakoda; H Fujioka; Y Matsuura; Y Takai
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

4.  Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion.

Authors:  Unnur Thorsteinsdottir; Aline Mamo; Evert Kroon; Lori Jerome; Janet Bijl; H Jeffrey Lawrence; Keith Humphries; Guy Sauvageau
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

Review 5.  DNA topoisomerases.

Authors:  J C Wang
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

6.  The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion.

Authors:  H G Ahuja; C A Felix; P D Aplan
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

7.  Nup98 is a mobile nucleoporin with transcription-dependent dynamics.

Authors:  Eric R Griffis; Nihal Altan; Jennifer Lippincott-Schwartz; Maureen A Powers
Journal:  Mol Biol Cell       Date:  2002-04       Impact factor: 4.138

8.  NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.

Authors:  J D E de Rooij; I H I M Hollink; S T C J M Arentsen-Peters; J F van Galen; H Berna Beverloo; A Baruchel; J Trka; D Reinhardt; E Sonneveld; M Zimmermann; T A Alonzo; R Pieters; S Meshinchi; M M van den Heuvel-Eibrink; C Michel Zwaan
Journal:  Leukemia       Date:  2013-03-27       Impact factor: 11.528

9.  CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity.

Authors:  L H Kasper; P K Brindle; C A Schnabel; C E Pritchard; M L Cleary; J M van Deursen
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

10.  NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.

Authors:  S Z Raza-Egilmez; S N Jani-Sait; M Grossi; M J Higgins; T B Shows; P D Aplan
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

View more
  6 in total

1.  Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Authors:  Jarno L Kivioja; Angeliki Thanasopoulou; Ashwini Kumar; Mika Kontro; Bhagwan Yadav; Muntasir M Majumder; Komal K Javarappa; Samuli Eldfors; Juerg Schwaller; Kimmo Porkka; Caroline A Heckman
Journal:  Leukemia       Date:  2018-12-19       Impact factor: 11.528

Review 2.  Nucleoporin genes in human diseases.

Authors:  Valeria Nofrini; Danika Di Giacomo; Cristina Mecucci
Journal:  Eur J Hum Genet       Date:  2016-04-13       Impact factor: 4.246

3.  NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.

Authors:  Haiming Xu; Daria G Valerio; Meghan E Eisold; Amit Sinha; Richard P Koche; Wenhuo Hu; Chun-Wei Chen; S Haihua Chu; Gerard L Brien; Christopher Y Park; James J Hsieh; Patricia Ernst; Scott A Armstrong
Journal:  Cancer Cell       Date:  2016-11-23       Impact factor: 31.743

Review 4.  Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets.

Authors:  C T Collins; J L Hess
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

Review 5.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

Review 6.  Deregulation of the HOXA9/MEIS1 axis in acute leukemia.

Authors:  Cailin T Collins; Jay L Hess
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.